MHH spin-off Cardior will be taken over for up to EUR 1.025 billion including an upfront payment and additional payments if certain development and commercial milestones are achieved.
Cardior has pioneered a new approach for the treatment of heart disease by targeting distinctive non-coding RNAs.
Cardior’s Phase II candidate CDR132L is supported by strong Phase I and preclinical data suggesting the compound is safe and able to achieve cardiac functional improvements.
A record number of over 270 innovators from academia and industry came together in Munich for this year’s BioVaria, one of Europe’s leading events boosting partnerships for the transfer of life-science inventions into application.